A late day move higher in shares of Novo Nordisk has been attributed to the company winning patent challenges related to its weight-loss therapy Wegovy. In afternoon trading, shares trading in New York are up $1.10, or 1%, to $92.04.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk announces FDA approval of Rivfloza injection for PH1
- Argus starts Novo Nordisk at Buy, sees valuation justified by growth outlook
- Novo Nordisk initiated with a Buy at Argus
- LLY, ISRG, or JNJ: Which Healthcare Stock Could Generate the Best Returns?
- Craig-Hallum upgrades WW to Hold amid enthusiasm for GLP-1 medications